Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 8:08 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 33,137 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PLACEBO Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics

NCT02953639
View directory record Official record
Conditions
Schizophrenia
Interventions
Basmisanil, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 50 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
37
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Nov 3, 2026, 8:08 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Light Treatment During Sleep on Young Men

NCT00796939
View directory record Official record
Conditions
Depression
Interventions
Green light mask, Red Light Mask
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
25 Years to 60 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2015 · Synced Nov 3, 2026, 8:08 PM EST
Completed Phase 4 Interventional Results available

Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

NCT01238575
View directory record Official record
Conditions
Pervasive Development Disorders
Interventions
placebo, extended-release guanfacine
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
5 Years to 14 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Nov 3, 2026, 8:08 PM EST
Terminated Phase 2 Interventional Results available

Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease

NCT03352557
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
BIIB092, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 80 Years
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Nov 3, 2026, 8:08 PM EST
Completed Phase 2 Interventional Results available

Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease

NCT02216357
View directory record Official record
Conditions
Aspirin Exacerbated Respiratory Disease (AERD)
Interventions
Ifetroban, Oral Capsule, Placebo, Oral Capsule
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
San Diego, California • Overland Park, Kansas • West Nyack, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Nov 3, 2026, 8:08 PM EST
Active, not recruiting Phase 3 Interventional Results available

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

NCT00114101
View directory record Official record
Conditions
DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma, Refractory Multiple Myeloma, Smoldering Multiple Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Lenalidomide, Melphalan, Peripheral Blood Stem Cell Transplantation, Placebo Administration
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2027
U.S. locations
140
States / cities
Scottsdale, Arizona • Duarte, California • Sacramento, California + 103 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Nov 3, 2026, 8:08 PM EST
Completed Phase 4 Interventional Results available

Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors

NCT00802919
View directory record Official record
Conditions
Schizophrenia, Cigarette Smoking
Interventions
Varenicline, Placebo for varenicline
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Nov 3, 2026, 8:08 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of MDMA on Social and Emotional Processing

NCT01849419
View directory record Official record
Conditions
Drug Addiction
Interventions
Within-subjects (MDMA), Within-subjects (oxytocin), Within-subjects (placebo)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Nov 3, 2026, 8:08 PM EST
Completed Not applicable Interventional

The Effect of Protandim on Non-alcoholic Steatohepatitis

NCT00977730
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
Protandim, Placebo
Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Nov 3, 2026, 8:08 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity

NCT06411730
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986368
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Nov 3, 2026, 8:08 PM EST
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides

NCT02261467
View directory record Official record
Conditions
Forehead Rhytides, Glabellar Rhytides
Interventions
OnabotulinumtoxinA, Normal Saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Birmingham, Alabama • Glendale, Arizona • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Nov 3, 2026, 8:08 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects

NCT02657122
View directory record Official record
Conditions
Healthy
Interventions
TD-1473 for SAD, Placebo for SAD, TD-1473 for MAD, Placebo for MAD
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Nov 3, 2026, 8:08 PM EST
Completed Phase 2 Interventional Results available

Phase 2 Study of Indomethacin Capsules to Treat Dental Pain

NCT00964431
View directory record Official record
Conditions
Dental Pain
Interventions
Celecoxib 400 mg, Placebo, Indomethacin Test (lower dose), Indomethacin Test (upper dose)
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Nov 3, 2026, 8:08 PM EST
Completed Phase 2 Interventional

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

NCT00476931
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
Interventions
SB-509, Placebo
Biological · Other
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
19
States / cities
La Jolla, California • Lakewood, California • Lomita, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Nov 3, 2026, 8:08 PM EST
Completed No phase listed Observational

Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease

NCT02298829
View directory record Official record
Conditions
Peyronie's Disease
Interventions
Subjects Previously Treated with AA4500
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 90 Years · Male only
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
30
States / cities
Anchorage, Alaska • Burbank, California • Laguna Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Nov 3, 2026, 8:08 PM EST
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis

NCT03421431
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
EDP-305 Dose 1, EDP-305 Dose 2, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
70
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Nov 3, 2026, 8:08 PM EST
Terminated Phase 4 Interventional Results available

Impact of Antibiotic Treatment on Prostate-Specific Antigen (PSA) Variability

NCT00596453
View directory record Official record
Conditions
Prostate Infections
Interventions
Ciprofloxacin hydrochloride, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 75 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Nov 3, 2026, 8:08 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants

NCT05760937
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986447, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Nov 3, 2026, 8:08 PM EST
Recruiting Phase 4 Interventional

Aspirin and Preeclampsia

NCT04479072
View directory record Official record
Conditions
Preeclampsia Postpartum
Interventions
Aspirin 81 mg, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Nov 3, 2026, 8:08 PM EST
Terminated Phase 3 Interventional Results available

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

NCT05026177
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Simufilam, Placebo
Drug
Lead sponsor
Cassava Sciences, Inc.
Industry
Eligibility
50 Years to 87 Years
Enrollment
1,125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
65
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Nov 3, 2026, 8:08 PM EST
Completed Phase 3 Interventional Results available

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

NCT01047501
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
80
States / cities
Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Nov 3, 2026, 8:08 PM EST
Completed Phase 3 Interventional

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

NCT00657501
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
testosterone gel, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
66
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Nov 3, 2026, 8:08 PM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Heat Therapy, Functional Capacity, and Vascular Health in Older Adults

NCT05706181
View directory record Official record
Conditions
Aging Well, Walking, Difficulty, Hyperemia
Interventions
Home-based leg heat therapy, Home-based sham therapy
Other
Lead sponsor
University of North Texas Health Science Center
Other
Eligibility
55 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Nov 3, 2026, 8:08 PM EST
Terminated Phase 4 Interventional Results available

Anxiety in Recovering Opiate Dependence

NCT00668265
View directory record Official record
Conditions
Generalized Anxiety Disorder, Comorbid Opiate Dependence in Remission, Status Post Methadone-Maintenance Treatment
Interventions
Quetiapine
Drug
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2013 · Synced Nov 3, 2026, 8:08 PM EST